This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Sibutramine

Authoring team

Sibutramine has been suspended in the UK amid fears that it increases the risk of heart attacks and strokes (1)

  • The European Medicines Agency (EMA) reviewed the obesity medicine sibutramine (Reductil) on the basis of safety information from a large clinical trial, the Sibutramine Cardiovascular OUTcomes (SCOUT) study. The review found that the cardiovascular risks of sibutramine outweigh its benefits. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended suspension of the marketing authorisation for this medicine across the European Union.

Reference:

1. Sibutramine: Suspension of marketing authorisation as risks outweigh benefits. Medicines and Healthcare products Regulatory Agency (MHRA), Jan 2010

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.